Teva Pharmaceutical Industries Ltd (TEVA) 64.41 $TEVA
Big Pharma Comes Under Attack From a New Hedge Fund Strategy
Sean Williams, The Motley Fool - Motley Fool - Sun Apr 26, 10:04AM CDT
Source: Teva Pharmaceutical, Facebook. Forget retail short-sellers and angry message board posters, Big Pharma has a much bigger concern on the horizon: hedge funds. I know what you're probably thinking, "Haven't various hedge funds already been...
ACT: 295.41 (-2.95), SHPG: 255.11 (-0.26), PFE: 35.27 (-0.09), JAZZ: 189.42 (+0.33), TEVA: 64.41 (+1.16)
TEVA Acquisition Of Mylan Would Produce Generic Powerhouse
Alpha Gen Capital - at Seeking Alpha - Sat Apr 25, 8:23AM CDT
PRGO: 192.89 (-8.74), MYL: 76.06 (+2.37), TEVA: 64.41 (+1.16), ASPX: 100.88 (-0.01)
Are Biosimilars the Next Big Thing in Biotech?
George Budwell, The Motley Fool - Motley Fool - Sat Apr 25, 6:06AM CDT
Biologics, or drugs developed from biological sources, have taken the pharma world by storm over the past decade or so. Five of the top 10 best-selling drugs in 2014, for example, were biologics indicated for either autoimmune disorders or cancer. ...
PFE: 35.27 (-0.09), MRK: 57.60 (+0.09), AMGN: 167.91 (-1.26), TEVA: 64.41 (+1.16), ABBV: 66.07 (+1.82), NVS: 104.28 (-1.22)
Perrigo rebuffs Mylan again
at Investor's Business Daily - Fri Apr 24, 6:12PM CDT
Over-the-counter pharma company Perrigo rejected generic-drug maker Mylan's (MYL) hostile $30-bil-plus acquisition bid. Perrigo said the bid was "significantly below" Mylan's prior offer that it had rejected as too low. Mylan's latest proposal would...
MYL: 76.06 (+2.37), TEVA: 64.41 (+1.16)
Mylan 'Raises' Perrigo Bid, But Teva Buzz Builds
at Investor's Business Daily - Fri Apr 24, 4:51PM CDT
Seeking to avoid being a takeover itself, Mylan (MYL) raised its offer for Perrigo (PRGO), which promptly rejected the bid, saying the proposal was worse than before. Generic drugmaker Mylan bid $60 cash and 2.2 Mylan shares for each share of...
ABT: 48.32 (-0.14), PRGO: 192.89 (-8.74), WBA: 85.98 (-0.71), WMT: 79.84 (+0.66), MYL: 76.06 (+2.37), TEVA: 64.41 (+1.16)
Teva-Active Biotech Start Phase II on MS Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 4:37PM CDT
Teva Pharmaceutical Industries Ltd. (TEVA) and Active Biotech started patient enrollment in a phase II study on laquinimod for primary progressive multiple sclerosis.
MNK: 122.01 (-2.84), TEVA: 64.41 (+1.16), MNTA: 20.13 (+0.04), NVS: 104.28 (-1.22)
Mylan makes official bid for Perrigo in generic drug contest
By MARLEY JAY - AP - Fri Apr 24, 4:03PM CDT
NEW YORK (AP) — Generic drugmaker Mylan is making official its offer for over-the-counter medicines maker Perrigo as it remains at the center of a three-way battle: Mylan wants to buy Perrigo, while a larger rival wants to buy Mylan.
TEVA: 64.41 (+1.16)
CoLucid Pharmaceuticals on deck for IPO
Seeking Alpha - at Seeking Alpha - Fri Apr 24, 2:52PM CDT
AGN: 240.22 (+2.88), JNJ: 101.08 (+0.62), ENDP: 93.27 (-0.81), ALDR: 25.10 (-0.25), AVNR: 16.96 (unch), CLCD: (), RDHL: 14.70 (+0.02), PTX: 7.09 (-0.24), AMGN: 167.91 (-1.26), DEPO: 27.65 (+0.36), TEVA: 64.41 (+1.16), OFIX: 36.46 (+0.10)
French biotech's B-vitamin beats placebo in Phase 3 MS study
Seeking Alpha - at Seeking Alpha - Fri Apr 24, 11:57AM CDT
BIIB: 401.71 (-28.57), OPXA: 0.43 (-0.01), FWP: 32.03 (-0.06), RCPT: 169.88 (-1.26), ABBV: 66.07 (+1.82), TEVA: 64.41 (+1.16), SNY: 51.75 (-0.01), CHRS: 23.52 (-0.88), NVS: 104.28 (-1.22)
Next Week In Biotech: Gilead, Celgene Report; PDUFAs For Theravance, The Medicines Co.
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 24, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
VRX: 210.42 (+1.03), BMRN: 120.28 (-2.67), UTHR: 186.69 (-1.87), CLDX: 30.10 (+0.19), ACOR: 33.12 (-0.38), AFFX: 12.44 (-0.16), HSP: 87.61 (-0.05), OXGN: 1.48 (unch), MACK: 13.42 (-0.25), HBIO: 6.22 (+0.08), ECYT: 6.17 (-0.13), GEVA: 108.51 (+0.92), CYTR: 5.13 (-0.13), THRX: 17.92 (+0.46), FF: 11.18 (+0.03), MDXG: 9.81 (-0.39), EXEL: 3.08 (-0.02), VRTX: 133.20 (-2.62), NEO: 4.75 (-0.11), PFE: 35.27 (-0.09), INCY: 107.34 (-0.51), MYL: 76.06 (+2.37), AMGN: 167.91 (-1.26), ANIK: 38.35 (-0.32), ALKS: 62.26 (-1.19), ONTY: 1.74 (-0.05), CELG: 118.71 (+2.62), NBIX: 43.37 (-0.31), SGEN: 37.14 (-0.36), OGXI: 2.19 (+0.04), EBIO: 11.19 (+0.69), ABAX: 63.62 (+0.31), GILD: 103.69 (-1.52), GERN: 4.30 (-0.03), HAE: 43.35 (+0.74), MRK: 57.60 (+0.09), TEVA: 64.41 (+1.16), PCRX: 85.07 (+0.80)
Intrauterine Contraceptive Devices Market (IUD/IUCD) - Type [Hormonal IUCD, Copper IUCD] - Global Forecast to 2019
M2 - Fri Apr 24, 6:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2cgx32/intrauterine) has announced the addition of the "Intrauterine Contraceptive Devices Market (IUD/IUCD),by Type [Hormonal IUCD, Copper IUCD] - Global Forecast to 2019" report to their offering. The global intrauterine contraceptive devices market is estimated to grow at a CAGR of 6.8% from 2014 to 2019 The growth of the intrauterine contraceptive devices market is driven by factors such as increasing rate of unplanned pregnancies, effective contraception and less side effects of IUCD, implementation of Affordable Care Act (ACA), rising initiatives of private firms directed towards reducing the expenses related to abortion, funds/grants for IUCD products, and technological advancements. However, high cost of treatment, threat of causing pelvic inflammatory infection (PID), threat of causing ectopic pregnancy, high rate of complications during unplanned pregnancy, and need of compulsory assistance of medical professional is hampering the growth of IUCD market. Moreover, rising number of players in this segment, technological advancements are creating growth opportunities for the global intrauterine contraceptive devices market. In this report, the market has been broadly classified on the basis of types which includes; Hormonal IUCD and Copper IUCD. The copper IUCD market segment is accounted for the largest market share of 51.9%. Geographically, the market in Asia accounted for the largest share of 35.0% of the Global Intrauterine Contraceptive Devices market in 2014, followed by Europe. The Intrauterine Contraceptive Devices market in the U.S. is primarily driven by Affordable Care Act, technological advancements. However, stringent regulatory and reimbursement policies in U.S., threat to PID infection are hampering the growth of the Intrauterine Contraceptive Devices market in this region. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Market Overview 5 Global Intrauterine Contraceptive Devices Market, By Type 6 Global Intrauterine Contraceptive Devices Market, By Product 7 Global Intrauterine Contraceptive Devices Market, By Geography 8 Global Intrauterine Contraceptive Devices Market: Competitive Landscape 9 Global Intrauterine Contraceptive Devices Market, By Company - Actavis Plc - Bayer Healthcare Ag (Subsidiary of Bayer Ag) - Medicine360 - Medisafe Distribution Inc. - OCON Medical Ltd. - PACE Pharmaceuticals, Inc. - SMB Corporation - Teva Pharmaceutical Industries Ltd. - Trimedic Supply Network Ltd. For more information visit http://www.researchandmarkets.com/research/2c...trauterine
TEVA: 64.41 (+1.16)
Will Biogen's (BIIB) Earnings Streak Continue in 1Q? - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Apr 23, 3:57PM CDT
Investor focus this quarter will remain on the performance of Biogen's (BIIB) oral MS treatment, Tecfidera.
BIIB: 401.71 (-28.57), UTHR: 186.69 (-1.87), TEVA: 64.41 (+1.16), BMY: 65.80 (-0.20)
Mylan Chooses Its Own Adventure
Chris DeMuth Jr. - at Seeking Alpha - Thu Apr 23, 2:27PM CDT
PRGO: 192.89 (-8.74), MYL: 76.06 (+2.37), TEVA: 64.41 (+1.16)
Teva and Active Biotech Announce First Patient Enrolled in Phase II Study Evaluating Laquinimod for Primary Progressive MS
GlobeNewswire - Thu Apr 23, 1:32PM CDT
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (TASE:TEVA) and Active Biotech (Stockholm:ACTI) today announced the first patient has been enrolled in the study A Randomized Placebo-controlled Trial Evaluating Laquinimod in PPMS, Gauging Gradations In MRI and Clinical Outcomes (ARPEGGIO), a Phase II study to evaluate laquinimod, an investigational, oral, immune modulator, for the treatment of primary progressive multiple sclerosis (PPMS). Currently there are no approved treatments for PPMS, representing a condition with a high unmet need.
TEVA: 64.41 (+1.16)
Teva Presents Data Comparing Early Treatment with COPAXONE(R) 40 mg/mL to Delayed Start Treatment at 67th American Academy of Neurology (AAN) Annual Meeting in Washington, D.C.
Business Wire - Thu Apr 23, 8:00AM CDT
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announces new 36-month data from the placebo-controlled and open-label extension phases of the Glatiramer Acetate Low-frequency Administration (GALA) study evaluating the efficacy and safety of three-times-a-week COPAXONE(R) (glatiramer acetate injection) 40 mg/mL in patients with relapsing forms of multiple sclerosis. The data will be featured during Poster Session 7 at the 67th American Academy of Neurology (AAN) meeting in Washington, D.C. on Thursday, April 23, 2015 from 2:00 p.m. - 6:30 p.m. ET.
TEVA: 64.41 (+1.16)
Will Teva Manage To Complete The Takeover Of Mylan?
Emerging Equities - at Seeking Alpha - Wed Apr 22, 4:44PM CDT
PRGO: 192.89 (-8.74), MYL: 76.06 (+2.37), TEVA: 64.41 (+1.16), ASPX: 100.88 (-0.01)
Fitch Places Teva Pharmaceutical's Ratings on Watch Negative on Proposed Mylan Acquisition
Business Wire - Wed Apr 22, 4:36PM CDT
Fitch Ratings has placed the ratings of Teva Pharmaceutical Industries Limited (NYSE: TEVA) and its subsidiaries, including the 'BBB+' long-term Issuer Default Rating, on Rating Watch Negative.
TEVA: 64.41 (+1.16)
Don't Cash In On Perrigo Yet, Upside Still Possible
Value Hawk - Seeking Alpha - Wed Apr 22, 4:27PM CDT
Summary: We recommend a sell for Perrigo Company (NYSE: PRGO ) with two triggers based on the possible scenarios. First, if Perrigo's price falls to $185, we recommend selling to protect significant gains from recent M&A conversations. On the...
PRGO: 192.89 (-8.74), MYL: 76.06 (+2.37), TEVA: 64.41 (+1.16)
Big Pharma Comes Under Attack From a New Hedge Fund Strategy
Sean Williams, The Motley Fool - Motley Fool - Sun Apr 26, 10:04AM CDT
Source: Teva Pharmaceutical, Facebook. Forget retail short-sellers and angry message board posters, Big Pharma has a much bigger concern on the horizon: hedge funds. I know what you're probably thinking, "Haven't various hedge funds already been...
ACT: 295.41 (-2.95), SHPG: 255.11 (-0.26), PFE: 35.27 (-0.09), JAZZ: 189.42 (+0.33), TEVA: 64.41 (+1.16)
TEVA Acquisition Of Mylan Would Produce Generic Powerhouse
Alpha Gen Capital - at Seeking Alpha - Sat Apr 25, 8:23AM CDT
PRGO: 192.89 (-8.74), MYL: 76.06 (+2.37), TEVA: 64.41 (+1.16), ASPX: 100.88 (-0.01)
Are Biosimilars the Next Big Thing in Biotech?
George Budwell, The Motley Fool - Motley Fool - Sat Apr 25, 6:06AM CDT
Biologics, or drugs developed from biological sources, have taken the pharma world by storm over the past decade or so. Five of the top 10 best-selling drugs in 2014, for example, were biologics indicated for either autoimmune disorders or cancer. ...
PFE: 35.27 (-0.09), MRK: 57.60 (+0.09), AMGN: 167.91 (-1.26), TEVA: 64.41 (+1.16), ABBV: 66.07 (+1.82), NVS: 104.28 (-1.22)
Perrigo rebuffs Mylan again
at Investor's Business Daily - Fri Apr 24, 6:12PM CDT
Over-the-counter pharma company Perrigo rejected generic-drug maker Mylan's (MYL) hostile $30-bil-plus acquisition bid. Perrigo said the bid was "significantly below" Mylan's prior offer that it had rejected as too low. Mylan's latest proposal would...
MYL: 76.06 (+2.37), TEVA: 64.41 (+1.16)
Mylan 'Raises' Perrigo Bid, But Teva Buzz Builds
at Investor's Business Daily - Fri Apr 24, 4:51PM CDT
Seeking to avoid being a takeover itself, Mylan (MYL) raised its offer for Perrigo (PRGO), which promptly rejected the bid, saying the proposal was worse than before. Generic drugmaker Mylan bid $60 cash and 2.2 Mylan shares for each share of...
ABT: 48.32 (-0.14), PRGO: 192.89 (-8.74), WBA: 85.98 (-0.71), WMT: 79.84 (+0.66), MYL: 76.06 (+2.37), TEVA: 64.41 (+1.16)
Teva-Active Biotech Start Phase II on MS Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 4:37PM CDT
Teva Pharmaceutical Industries Ltd. (TEVA) and Active Biotech started patient enrollment in a phase II study on laquinimod for primary progressive multiple sclerosis.
MNK: 122.01 (-2.84), TEVA: 64.41 (+1.16), MNTA: 20.13 (+0.04), NVS: 104.28 (-1.22)
Mylan makes official bid for Perrigo in generic drug contest
By MARLEY JAY - AP - Fri Apr 24, 4:03PM CDT
NEW YORK (AP) — Generic drugmaker Mylan is making official its offer for over-the-counter medicines maker Perrigo as it remains at the center of a three-way battle: Mylan wants to buy Perrigo, while a larger rival wants to buy Mylan.
TEVA: 64.41 (+1.16)
CoLucid Pharmaceuticals on deck for IPO
Seeking Alpha - at Seeking Alpha - Fri Apr 24, 2:52PM CDT
AGN: 240.22 (+2.88), JNJ: 101.08 (+0.62), ENDP: 93.27 (-0.81), ALDR: 25.10 (-0.25), AVNR: 16.96 (unch), CLCD: (), RDHL: 14.70 (+0.02), PTX: 7.09 (-0.24), AMGN: 167.91 (-1.26), DEPO: 27.65 (+0.36), TEVA: 64.41 (+1.16), OFIX: 36.46 (+0.10)
French biotech's B-vitamin beats placebo in Phase 3 MS study
Seeking Alpha - at Seeking Alpha - Fri Apr 24, 11:57AM CDT
BIIB: 401.71 (-28.57), OPXA: 0.43 (-0.01), FWP: 32.03 (-0.06), RCPT: 169.88 (-1.26), ABBV: 66.07 (+1.82), TEVA: 64.41 (+1.16), SNY: 51.75 (-0.01), CHRS: 23.52 (-0.88), NVS: 104.28 (-1.22)
Next Week In Biotech: Gilead, Celgene Report; PDUFAs For Theravance, The Medicines Co.
SA Editor Mike Taylor - Seeking Alpha - Fri Apr 24, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
VRX: 210.42 (+1.03), BMRN: 120.28 (-2.67), UTHR: 186.69 (-1.87), CLDX: 30.10 (+0.19), ACOR: 33.12 (-0.38), AFFX: 12.44 (-0.16), HSP: 87.61 (-0.05), OXGN: 1.48 (unch), MACK: 13.42 (-0.25), HBIO: 6.22 (+0.08), ECYT: 6.17 (-0.13), GEVA: 108.51 (+0.92), CYTR: 5.13 (-0.13), THRX: 17.92 (+0.46), FF: 11.18 (+0.03), MDXG: 9.81 (-0.39), EXEL: 3.08 (-0.02), VRTX: 133.20 (-2.62), NEO: 4.75 (-0.11), PFE: 35.27 (-0.09), INCY: 107.34 (-0.51), MYL: 76.06 (+2.37), AMGN: 167.91 (-1.26), ANIK: 38.35 (-0.32), ALKS: 62.26 (-1.19), ONTY: 1.74 (-0.05), CELG: 118.71 (+2.62), NBIX: 43.37 (-0.31), SGEN: 37.14 (-0.36), OGXI: 2.19 (+0.04), EBIO: 11.19 (+0.69), ABAX: 63.62 (+0.31), GILD: 103.69 (-1.52), GERN: 4.30 (-0.03), HAE: 43.35 (+0.74), MRK: 57.60 (+0.09), TEVA: 64.41 (+1.16), PCRX: 85.07 (+0.80)
Intrauterine Contraceptive Devices Market (IUD/IUCD) - Type [Hormonal IUCD, Copper IUCD] - Global Forecast to 2019
M2 - Fri Apr 24, 6:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2cgx32/intrauterine) has announced the addition of the "Intrauterine Contraceptive Devices Market (IUD/IUCD),by Type [Hormonal IUCD, Copper IUCD] - Global Forecast to 2019" report to their offering. The global intrauterine contraceptive devices market is estimated to grow at a CAGR of 6.8% from 2014 to 2019 The growth of the intrauterine contraceptive devices market is driven by factors such as increasing rate of unplanned pregnancies, effective contraception and less side effects of IUCD, implementation of Affordable Care Act (ACA), rising initiatives of private firms directed towards reducing the expenses related to abortion, funds/grants for IUCD products, and technological advancements. However, high cost of treatment, threat of causing pelvic inflammatory infection (PID), threat of causing ectopic pregnancy, high rate of complications during unplanned pregnancy, and need of compulsory assistance of medical professional is hampering the growth of IUCD market. Moreover, rising number of players in this segment, technological advancements are creating growth opportunities for the global intrauterine contraceptive devices market. In this report, the market has been broadly classified on the basis of types which includes; Hormonal IUCD and Copper IUCD. The copper IUCD market segment is accounted for the largest market share of 51.9%. Geographically, the market in Asia accounted for the largest share of 35.0% of the Global Intrauterine Contraceptive Devices market in 2014, followed by Europe. The Intrauterine Contraceptive Devices market in the U.S. is primarily driven by Affordable Care Act, technological advancements. However, stringent regulatory and reimbursement policies in U.S., threat to PID infection are hampering the growth of the Intrauterine Contraceptive Devices market in this region. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Market Overview 5 Global Intrauterine Contraceptive Devices Market, By Type 6 Global Intrauterine Contraceptive Devices Market, By Product 7 Global Intrauterine Contraceptive Devices Market, By Geography 8 Global Intrauterine Contraceptive Devices Market: Competitive Landscape 9 Global Intrauterine Contraceptive Devices Market, By Company - Actavis Plc - Bayer Healthcare Ag (Subsidiary of Bayer Ag) - Medicine360 - Medisafe Distribution Inc. - OCON Medical Ltd. - PACE Pharmaceuticals, Inc. - SMB Corporation - Teva Pharmaceutical Industries Ltd. - Trimedic Supply Network Ltd. For more information visit http://www.researchandmarkets.com/research/2c...trauterine
TEVA: 64.41 (+1.16)
Will Biogen's (BIIB) Earnings Streak Continue in 1Q? - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Apr 23, 3:57PM CDT
Investor focus this quarter will remain on the performance of Biogen's (BIIB) oral MS treatment, Tecfidera.
BIIB: 401.71 (-28.57), UTHR: 186.69 (-1.87), TEVA: 64.41 (+1.16), BMY: 65.80 (-0.20)
Mylan Chooses Its Own Adventure
Chris DeMuth Jr. - at Seeking Alpha - Thu Apr 23, 2:27PM CDT
PRGO: 192.89 (-8.74), MYL: 76.06 (+2.37), TEVA: 64.41 (+1.16)
Teva and Active Biotech Announce First Patient Enrolled in Phase II Study Evaluating Laquinimod for Primary Progressive MS
GlobeNewswire - Thu Apr 23, 1:32PM CDT
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (TASE:TEVA) and Active Biotech (Stockholm:ACTI) today announced the first patient has been enrolled in the study A Randomized Placebo-controlled Trial Evaluating Laquinimod in PPMS, Gauging Gradations In MRI and Clinical Outcomes (ARPEGGIO), a Phase II study to evaluate laquinimod, an investigational, oral, immune modulator, for the treatment of primary progressive multiple sclerosis (PPMS). Currently there are no approved treatments for PPMS, representing a condition with a high unmet need.
TEVA: 64.41 (+1.16)
Teva Presents Data Comparing Early Treatment with COPAXONE(R) 40 mg/mL to Delayed Start Treatment at 67th American Academy of Neurology (AAN) Annual Meeting in Washington, D.C.
Business Wire - Thu Apr 23, 8:00AM CDT
Teva Pharmaceutical Industries Ltd., (NYSE:TEVA) today announces new 36-month data from the placebo-controlled and open-label extension phases of the Glatiramer Acetate Low-frequency Administration (GALA) study evaluating the efficacy and safety of three-times-a-week COPAXONE(R) (glatiramer acetate injection) 40 mg/mL in patients with relapsing forms of multiple sclerosis. The data will be featured during Poster Session 7 at the 67th American Academy of Neurology (AAN) meeting in Washington, D.C. on Thursday, April 23, 2015 from 2:00 p.m. - 6:30 p.m. ET.
TEVA: 64.41 (+1.16)
Will Teva Manage To Complete The Takeover Of Mylan?
Emerging Equities - at Seeking Alpha - Wed Apr 22, 4:44PM CDT
PRGO: 192.89 (-8.74), MYL: 76.06 (+2.37), TEVA: 64.41 (+1.16), ASPX: 100.88 (-0.01)
Fitch Places Teva Pharmaceutical's Ratings on Watch Negative on Proposed Mylan Acquisition
Business Wire - Wed Apr 22, 4:36PM CDT
Fitch Ratings has placed the ratings of Teva Pharmaceutical Industries Limited (NYSE: TEVA) and its subsidiaries, including the 'BBB+' long-term Issuer Default Rating, on Rating Watch Negative.
TEVA: 64.41 (+1.16)
Don't Cash In On Perrigo Yet, Upside Still Possible
Value Hawk - Seeking Alpha - Wed Apr 22, 4:27PM CDT
Summary: We recommend a sell for Perrigo Company (NYSE: PRGO ) with two triggers based on the possible scenarios. First, if Perrigo's price falls to $185, we recommend selling to protect significant gains from recent M&A conversations. On the...
PRGO: 192.89 (-8.74), MYL: 76.06 (+2.37), TEVA: 64.41 (+1.16)
